<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04130828</url>
  </required_header>
  <id_info>
    <org_study_id>REC.62-404-14-1</org_study_id>
    <nct_id>NCT04130828</nct_id>
  </id_info>
  <brief_title>Thrice-weekly Versus Thrice-daily Oral Ferrous Fumarate Treatment in Adult Patients With Iron Deficiency Anemia</brief_title>
  <official_title>Thrice-weekly Versus Thrice-daily Oral Ferrous Fumarate Treatment in Adult Patients With Iron Deficiency Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prince of Songkla University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Thai Society of Hematology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Prince of Songkla University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iron deficiency anemia is a global health problem and the most common cause of anemia&#xD;
      worldwide. Patients with iron deficiency and Iron deficiency anemia can present with a&#xD;
      multitude of symptoms including fatigue, dyspnea on exertion, dysphagia, pallor,&#xD;
      palpitations, headaches, tinnitus, taste disturbance and pica. Oral iron supplementation is&#xD;
      associated with increasing hemoglobin in multiple studies in women, pregnant women and&#xD;
      elderly patients. However, the optimal dose and frequency of oral iron supplementation for&#xD;
      treatment remains unclear. The current proposed study attempts to address this gap in the&#xD;
      literature.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patient who achieved hemoglobin target</measure>
    <time_frame>12 weeks</time_frame>
    <description>Hemoglobin achieved 12 g/dL in women, 13 g/dL in men and or increased 1g/dL/4weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>Thrice-weekly group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferrous fumarate 200 mg PO PC Thrice-weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thrice-daily group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferrous fumarate 200 mg PO PC Thrice-daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous Fumarate</intervention_name>
    <description>Ferrous fumarate 200 mg PO PC</description>
    <arm_group_label>Thrice-daily group</arm_group_label>
    <arm_group_label>Thrice-weekly group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-60 years&#xD;
&#xD;
          -  Outpatients with iron deficiency anemia defined as hemoglobin less than 12 g/dL in&#xD;
             women or 13 g/dL in men; AND ferritin less than 30 ng/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to iron&#xD;
&#xD;
          -  Allergy to albendazole&#xD;
&#xD;
          -  Currently pregnancy&#xD;
&#xD;
          -  Currently breastfeeding&#xD;
&#xD;
          -  Known history of inflammatory bowel disease, celiac disease, inherited bleeding&#xD;
             disorder, solid cancer, hematologic cancer or thalassemia&#xD;
&#xD;
          -  Renal impairment or glomerular filtration rate less than 30 ml/min/1.73m2&#xD;
&#xD;
          -  Hepatic impairment or Child Pugh score more than 7&#xD;
&#xD;
          -  Active bleeding define hemoglobin decrease more than 2 g/dL&#xD;
&#xD;
          -  Multivitamin and mineral supplement (35 mg or more of elemental iron per day) in 2&#xD;
             weeks prior to randomization&#xD;
&#xD;
          -  Non-literate&#xD;
&#xD;
        Subject withdrawal criteria:&#xD;
&#xD;
          -  Intolerance to drugs&#xD;
&#xD;
          -  Active bleeding define hemoglobin decrease more than 2 g/dL&#xD;
&#xD;
          -  Major surgery&#xD;
&#xD;
          -  Blood transfusion&#xD;
&#xD;
          -  Loss follow-up more than 2 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Siddhibhong Jongkraijakra, Doctor of Pharmacy</last_name>
    <phone>66896441419</phone>
    <email>siddhibhong.j@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Songklanagarind Hospital</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkhla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siddhibhong Jongkraijakra, Doctor of Pharmacy</last_name>
      <email>siddhibhong.j@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2019</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prince of Songkla University</investigator_affiliation>
    <investigator_full_name>Siddhibhong Jongkraijakra</investigator_full_name>
    <investigator_title>Faculty of Pharmaceutical scienes</investigator_title>
  </responsible_party>
  <keyword>ferrous fumarate</keyword>
  <keyword>oral iron treatment</keyword>
  <keyword>thrice-weekly</keyword>
  <keyword>thrice-daily</keyword>
  <keyword>iron deficiency anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrous fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

